We were  honoured to be recognised for our innovative business model, and our approach to antiviral development at the Nelson Tasman Chamber of Commerce Business Awards.

In this article we will answer some of the questions we get asked about our work. If you have a question you’d like answered, please email us.

Nelson biotech company Kimer Med is expanding into a new laboratory and looking to hire additional staff after signing an agreement with Cawthron Institute this week.

The current monkeypox outbreak continues to cause concern, not least because there are no specific antivirals to treat this infection. As attention turns to rapidly repurposing other drugs in the hope that they might prove to be effective, the situation highlights just how vital our work to develop a broad-spectrum antiviral drug is.

An international team of scientists is now monitoring a newly-identified and potentially dangerous virus that is believed to have ‘jumped’ from animals to humans.

More than 3,000 people die every day from liver disease caused by viral hepatitis, and today (July 28) is World Hepatitis Day.

We are thrilled to receive this significant support in the form of R&D funding, and see it as recognition of the important science that we are undertaking.

Vaccines are designed to pre-arm your immune system to recognise and defend the body against a particular virus, and therefore need to be administered before you are infected.

There are a few questions that seem to come up with almost every extended conversation about Kimer Med and what we’re doing.

With a broad-spectrum antiviral such as VTose, one of the most common questions we get is whether it will work on particular viruses.

Let’s start with how human cells normally defend themselves against viruses. One way this works is through antibodies. These large, Y-shaped proteins are produced by plasma B cells, a type of white blood cell.